by Rod Raynovich | Jun 28, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Auxilium (AUXL) shares held up today ($24.85 up 0.65%) after a June 28 article questioned the valuation of the stock. Revenues for the last quarter were $45.5M primarily from its Testim testosterone gel, with a loss of $8.6M.Analysts have high expectations for a...
by Rod Raynovich | Jun 28, 2010 | RAG
Here is an update on Oncology Pipelines courtesy of Linda Pullan (lpullan@msn.com), a consultant who follows the sector. www.PullanConsulting.com Pfizer (PFE), Roche (RHHBY) and Novartis (NVS) are predicted to launch the most drugs. Some Pharma Companies Need to...
by Rod Raynovich | Jun 25, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Supergen (SUPG) has been moving up steadily over the past few days since its low in the $2.10+ range this week.SUPG is in the Rayno Life Science Portfolio. The April 15,2010 high was $3.72.The balance sheet is strong with over $100M in cash,Shareholder Equity of $106M...
by Rod Raynovich | Jun 24, 2010 | BIOgraph
Market Risk is Up-Speculation Is Off-Look for Value The news out of ASCO was not that new and exciting but it is even harder to find anything positive to write about three weeks later. Investors are “hiding out”. The overall market has cooled down from the...
by Rod Raynovich | Jun 15, 2010 | BIOgraph
Large Cap drug stocks have rallied over the past week as the market was up overall but also because the Euro was up 3% over the past 4 days. Is the correlation there? Well look at these charts tracking drug multinationals and the Euro through the ETF FXE. Pfizer (PFE)...
by Rod Raynovich | Jun 14, 2010 | RAG
Genomics and Medicine: transformative therapies are coming but diagnostic breakthroughs will lead the way Ten years after the start of the Human Genome Project we have learned a lot about the links between genetics and disease but few direct cures have emerged. The...
by Rod Raynovich | Jun 10, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Any momentum in biotech stocks from ASCO have been eclipsed by bearish, volatile trends overall. There were some nice moves up today with the Rayno Life Science Portfolio was up 2.67% and all bio ETF’s did well: FBT up 3%,XBI up 3.48%, and IBB up 3.11%. Among...
by Rod Raynovich | Jun 7, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Two Big Winners in Bristol Myers Squibb and Celgene The American Society of Oncology Meeting is normally good times for biotech as scientific and clinical developments propel stocks. This year the personalized medicine theme with potential breakthroughs in targeted...
by Rod Raynovich | Jun 4, 2010 | 2024-25 Life Science Portfolios, BIOgraph
In a nasty market where many indices are down 2.5% or more Cubist bucks the trend up 3% apparently on a Cowen and Co. upgrade from Neutral to Outperform.As of midday trading with a Volume of 2.8M shares the stock is at $22.25 up from $21.5 yesterday. The stock is up...
